Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | CD44 | P16070 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 6/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.34 |
| ▸ | CA2 | P00918 | 4/20 | 0.34 |
| ▸ | CA9 | Q16790 | 4/20 | 0.34 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA7 | P43166 | 3/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA6 | P23280 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 2/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30490095 | 0.86 | GAA (0.53) | GAACD44FLT1AHRTSHR | |
| SCHEMBL2264764 | 0.86 | GAA (0.53) | GAACD44FLT1AHRTSHR | |
| SCHEMBL2766461 | 0.86 | GAA (0.53) | GAACD44FLT1AHRTSHR | |
| SCHEMBL5518300 | 0.78 | PTK2 (0.50) | GAACA1CA2CA9CA12 | |
| SCHEMBL9974977 | 0.78 | CYP3A4 (0.41) | GAAFLT1AHRTSHRCYP3A4 | |
| SCHEMBL31401806 | 0.77 | GAA (0.43) | GAACD44FLT1AHRTSHR | |
| SCHEMBL1306767 | 0.77 | GAA (0.43) | GAACD44TSHRCYP3A4TP53 | |
| SCHEMBL14741306 | 0.77 | AHR (0.44) | GAACD44AHRTSHRCYP3A4 | |
| SCHEMBL404666 | 0.77 | CD44 (0.65) | GAACD44TSHRCYP3A4TP53 | |
| SCHEMBL27708042 | 0.77 | ALDH1A1 (0.47) | GAACD44TSHRCYP3A4CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49948-E1 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| EP-3268362-B1 | SUBSTITUTED PYRIDINES AND USES THEREOF | PELOTON THERAPEUTICS INC (US) | 2021-10-20 | — | — | EP | disclosed |
| CN-110372550-B | Aryl ethers and their use | 佩洛通治疗公司 | 2021-08-24 | — | — | CN | disclosed |
| US-10807948-B2 | Aromatic compounds and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10786480-B2 | Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| EP-3417851-B1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS INC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20200190031-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-10597366-B2 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| EP-3417852-B1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS INC (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-3043784-B9 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS INC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20160368893-A1 | CYCLIC SULFONE AND SULFOXIMINE ANALOGS AND USES THEREOF | Peloton Therapeutics ,Inc. | 2016-12-22 | — | — | US | disclosed |
| US-20160362390-A1 | TRICYCLIC INHIBITORS OF HIF-2-ALPHA AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2016-12-15 | — | — | US | disclosed |
| EP-3083639-A1 | CYCLIC SULFONE AND SULFOXIMINE ANALOGS AND USES THEREOF | Peloton Therapeutics, Inc. (US) | 2016-10-26 | — | — | EP | disclosed |
| WO-2016145045-A1 | COMPOSITIONS FOR USE IN TREATING GLIOBLASTOMA | PELOTON THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| WO-2016144825-A1 | AROMATIC COMPOUNDS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| US-20160251307-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| EP-3043784-A1 | ARYL ETHERS AND USES THEREOF | Peloton Therapeutics, Inc. (US) | 2016-07-20 | — | — | EP | disclosed |
| WO-2016057242-A1 | HIF-2α INHIBITORS FOR TREATING IRON OVERLOAD DISORDERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2015095048-A1 | CYCLIC SULFONE AND SULFOXIMINE ANALOGS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015035223-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10786480-B2 | Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof | HIF1AN, HIF1A, EGLN2 | GAA 758/4885CD44 443/4885FLT1 64/4885 |
| US-20160251307-A1 | ARYL ETHERS AND USES THEREOF | HIF1AN, EGLN2, VHL | GAA 841/4885CD44 2283/4885FLT1 11/4885 |
| US-20160368893-A1 | CYCLIC SULFONE AND SULFOXIMINE ANALOGS AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | GAA 2282/4885CD44 480/4885FLT1 610/4885 |
| US-20200190031-A1 | ARYL ETHERS AND USES THEREOF | HIF1AN, EGLN2, VHL | GAA 841/4885CD44 2283/4885FLT1 11/4885 |
| US-10597366-B2 | Aryl ethers and uses thereof | HIF1AN, EGLN2, VHL | GAA 841/4885CD44 2283/4885FLT1 11/4885 |
| US-10807948-B2 | Aromatic compounds and uses thereof | VHL, HIF1AN, HIF1A | GAA 433/4885CD44 1171/4885FLT1 227/4885 |
| US-20160362390-A1 | TRICYCLIC INHIBITORS OF HIF-2-ALPHA AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | GAA 410/4885CD44 2563/4885FLT1 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.